鼠李糖乳桿菌 GG Lactobacillus rhamnosus GG (LGG) × 克隆氏症
結論：主流反證據
本配對具備明確的菌株特異性證據反向結果：2005 年 Bousvaros 等人針對兒童克隆氏症的雙盲 RCT（n=75，strain-exact LGG）顯示 LGG 復發率 31% vs 安慰劑 17%，未延長至復發時間；2009 年 Rolfe 等統合分析（strain-exact）更進一步警告 LGG 作為維持治療『可能增加復發率』。
D 🔴 D 反證據 主流反證據 ⚠️ medium — moderate promotional content
本配對具備明確的菌株特異性證據反向結果：2005 年 Bousvaros 等人針對兒童克隆氏症的雙盲 RCT（n=75，strain-exact LGG）顯示 LGG 復發率 31% vs 安慰劑 17%，未延長至復發時間；2009 年 Rolfe 等統合分析（strain-exact）更進一步警告 LGG 作為維持治療『可能增加復發率』。
L5b（Mayo）、L5d（Harvard）為 species/generic 層級的負面或謹慎立場，L5e（ACG）明確表示『Probiotics do not seem to help people with Crohn's』。
EFSA（L4b）亦拒絕所有 LGG 腸胃健康宣稱。
strain-exact 證據與 generic 證據一致指向『無效甚至有害』，符合 D（against）等級。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.28
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 主流反證據
信心度
72%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.278
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (3 negative > 1 positive)，下層 RCT 不能推翻
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Probiotics for maintenance of remission in Crohn's disease
結論：Across 7 small trials no probiotic (including LGG) beat placebo: LGG after medical remission RR 0.83 (95% CI 0.25-2.80), after surgical remission RR 1.58 (95% CI 0.30-8.40), and in children RR 1.85 (95% CI 0.77-4.40) — all non-significant, with the authors concluding there is no evidence probiotics are beneficial for maintaining CD remission.
前往 PubMed Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease
結論：Pooled across 6 RCTs Lactobacilli did not reduce clinical relapse (RR 1.15, 95% CI 0.90-1.48), and the strain-exact L. rhamnosus GG subgroup showed significantly INCREASED relapse (RR 1.68, 95% CI 1.07-2.64), prompting the authors to warn that LGG maintenance 'may increase the relapse rates of Crohn disease.'
前往 PubMed A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease
結論：Adding LGG did not prolong remission: 31% (12/39) relapsed on LGG vs 17% (6/36) on placebo (P=0.18), with median time to relapse 9.8 months on LGG vs 11.0 months on placebo (P=0.24) — numerically worse on LGG but not statistically significant.
前往 PubMed Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG
結論：Among the 37 patients in clinical remission, endoscopic recurrence occurred in 60% (9/15) on LGG vs 35.3% (6/17) on placebo (P=0.297), and the authors concluded LGG neither prevents endoscopic recurrence nor reduces lesion severity after surgery.
前往 PubMed Efficacy and safety of probiotics in the induction and maintenance of inflammatory bowel disease remission: a systematic review and meta-analysis
結論：In this newer pooled analysis (10 RCTs, 777 UC+CD patients; not LGG-specific) probiotics showed no benefit for maintaining Crohn's remission (RR 0.80, 95% CI 0.61-1.06, P=0.12), with the authors concluding probiotics have 'no obvious therapeutic advantage in maintaining CD' remission.
前往 PubMed Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease
結論：Across 14 Crohn's disease studies (not LGG-specific) multiple probiotic-vs-placebo comparisons showed no significant difference in clinical outcomes, and the review concluded there is 'insufficient data to recommend probiotics for use in CD' while supporting their use in UC and pouchitis.
前往 PubMed L4a US FDA
支持
GRN No. 231 — Notified Substance: Lactobacillus casei subsp. rhamnosus strain GG. Intended Use: Ingredient in term infant formula, at levels not to exceed 10^8 colony forming units per gram of powdered formula. Notifier: Mead Johnson & Company. Agency Response: FDA has no questions (closure date: May 29, 2008). 來源↗
L4b EU EFSA
謹慎
The bacterial species L. rhamnosus (now Lacticaseibacillus rhamnosus) is considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to safety assessment. However, the EFSA Panel on Dietetic Products, Nutrition and Allergies concluded that a cause and effect relationship has not been established between the consumption of Lactobacillus rhamnosus GG (ATCC 53103, LGG)… 來源↗
L4c UK NHS
中性
Probiotics are generally classed as food rather than medicine, which means they don't go through the rigorous testing medicines do. ... For most people, probiotics appear to be safe. If you want to try them, and you have a healthy immune system, they shouldn't cause any unpleasant side effects. ... If you have an existing health condition or a weakened immune system, you should talk to a doctor… 來源↗
L4d TW TFDA / 衛福部
支持
Lactobacillus rhamnosus is listed in the 'Food Ingredients Available for Use' (可供食品使用原料) comprehensive list as a lactic acid bacterium (乳酸菌), in the form of bacterial cells (菌體), and can be used as a food ingredient or for food processing purposes. 來源↗
L4e WHO
支持
Administration of Lacticaseibacillus rhamnosus GG (LGG) to children with gastroenteritis is recommended by universal guidelines. The World Gastroenterology Organisation's Global Guidelines for Probiotics and Prebiotics (2023 update) lists LGG as having documented, positive results in multiple gut-related health areas. The FAO/WHO Joint Working Group (London, Ontario, 2002) 'Guidelines for the E… 來源↗
L5a NIH Office of Dietary Supplements
支持
Lactobacillus rhamnosus GG is an example where Lactobacillus is the genus, rhamnosus is the species, and GG is the strain. Treatment with LGG compared with placebo or no additional treatment reduced the risk of antibiotic-associated diarrhea in patients treated with antibiotics from 22.4% to 12.3% (relative risk: 0.49). However, when children and adults were evaluated separately, the difference… 來源↗
L5b Mayo Clinic
謹慎
there is very little evidence to justify the use of probiotics for the treatment of Crohn's disease 來源↗
L5c Cleveland Clinic
中性
Inflammatory bowel diseases, like ulcerative colitis and Crohn's disease ... Taking oral probiotics might help prevent or treat these conditions, although results may vary. The Lactobacillus genus, including L. acidophilus, L. rhamnosus, L. casei and L. plantarum. 來源↗
L5d Harvard Health
謹慎
Probiotics have not been studied as rigorously in Crohn's disease as in ulcerative colitis. Most of the limited set of studies found that probiotics are no better than placebo in reducing symptoms or promoting remission. 來源↗
L5e Specialty Society (condition-mapped)
反對
Probiotics do not seem to help people with Crohn's. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 中度
低中高
📍立場總覽
台灣 PTT、Dcard、mobile01 等社群搜尋未發現針對 LGG (鼠李糖乳桿菌 GG / Culturelle 康萃樂) 與克隆氏症的個案討論；現有 LGG 心得多集中在女性私密處保養、腹瀉、過敏、乳糖不耐等議題，克隆氏症相關討論則以泛指的「益生菌」為主，並非針對特定菌株。
💬社群實感
資料不足
破解迷思 社群最常見的 2 個誤解
✓
事實誤以為所有「鼠李糖乳桿菌」菌株效果相同 (LGG 與 GR-1 為不同菌株，用途不同)
✓
事實誤以為益生菌可取代克隆氏症的常規藥物治療 (如 5-ASA、生物製劑)
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- Culturelle 康萃樂
- iHerb 代購 LGG 系列
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳
葡萄王LGG特益菌 — 許可證字號：衛署健食字第A00028號，功效：有助於增加腸內乳酸菌菌數。主要成分為乳酸菌凍乾品 (Lactobacillus rhamnosus GG)。
代表來源 ↗ L10b · TFDA 法定身份 官方認定
✅健康食品（小綠人）
鼠李糖乳酸桿菌（Lactobacillus rhamnosus）被列為微生物及其來源製取之原料，其菌體可供為食品原料或食品加工使用。在台灣，益生菌基本上歸類為「食品」，由食藥署（TFDA）管理，主要規範標示與安全性，避免虛假功效宣稱。若產品要宣稱「輔助調整過敏體質」或「改善胃腸功能」等保健功效，必須通過審查並取得健康食品（小綠人）標章。
來源 ↗- 生物製劑 (anti-TNF, IL-23 inhibitors)
- 免疫調節劑 (azathioprine, MTX)
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-crohn-disease-INT-lactobacillus-rhamnosus-gg-001/",
"datePublished": "2026-06-09",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "鼠李糖乳桿菌 GG能改善克隆氏症",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 1,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔴 D 反證據"
}
}